Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 3616 AL 3630

Tonic GABAA Receptors as Potential Target for the Treatment of Temporal Lobe Epilepsy

Schipper S, Aalbers MW, Rijkers K, Swijsen A, Rigo JM, Hoogland G, Vles JS.

Mol Neurobiol. 2016 Oct;53(8):5252-65. doi: 10.1007/s12035-015-9423-8. Epub 2015 Sep 26.

Down-regulation of B cell-related genes in peripheral blood leukocytes of Parkinson's disease patients with and without GBA mutations

Kobo H, Bar-Shira A, Dahary D, Gan-Or Z, Mirelman A, Goldstein O, Giladi N, Orr-Urtreger A.

Mol Genet Metab. 2016 Feb;117(2):179-85. doi: 10.1016/j.ymgme.2015.09.005. Epub 2015 Sep 14.

Therapy-resistant symptoms in Parkinson's disease

Vorovenci RJ, Biundo R, Antonini A.

J Neural Transm (Vienna). 2016 Jan;123(1):19-30. doi: 10.1007/s00702-015-1463-8. Epub 2015 Sep 26.

Cognitive impairment in Parkinson's disease and dementia with Lewy bodies

Aarsland D.

Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S144-8. doi: 10.1016/j.parkreldis.2015.09.034. Epub 2015 Sep 21.

Adaptive deep brain stimulation in Parkinson's disease

Beudel M, Brown P.

Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1(Suppl 1):S123-6. doi: 10.1016/j.parkreldis.2015.09.028. Epub 2015 Sep 15.

Genetic susceptibility variants in parkinsonism

Soto-Ortolaza AI, Ross OA.

Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1(0 1):S7-11. doi: 10.1016/j.parkreldis.2015.09.011. Epub 2015 Sep 7.

Abnormal behaviours during pramipexole treatment for Cotard's syndrome: a case report

Maruo J, Haraguchi Y, Tateishi H, Noguchi T, Mizoguchi Y, Kato TA, Kawashima T, Monji A.

Psychogeriatrics. 2016 Jul;16(4):283-286. doi: 10.1111/psyg.12148. Epub 2015 Sep 29.

Interventional trials in atypical parkinsonism

Eschlböck S, Krismer F, Wenning GK.

Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S82-92. doi: 10.1016/j.parkreldis.2015.09.038. Epub 2015 Sep 25.

From rare to common and back again: 60years of lysosomal dysfunction

Coutinho MF, Alves S.

Mol Genet Metab. 2016 Feb;117(2):53-65. doi: 10.1016/j.ymgme.2015.08.008. Epub 2015 Aug 18.

Potential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimer's and Parkinson's diseases

Shetty AK, Bates A.

Brain Res. 2016 May 1;1638(Pt A):74-87. doi: 10.1016/j.brainres.2015.09.019. Epub 2015 Sep 28.

Non-motor symptoms and quality of life in patients with Parkinson's disease in Northeastern Mexico

Estrada-Bellmann I, Camara-Lemarroy CR, Calderon-Hernandez HJ, Rocha-Anaya JJ, Villareal-Velazquez HJ.

Acta Neurol Belg. 2016 Jun;116(2):157-61. doi: 10.1007/s13760-015-0544-7. Epub 2015 Sep 30.

Validity and reliability of an IMU-based method to detect APAs prior to gait initiation

Mancini M, Chiari L, Holmstrom L, Salarian A, Horak FB.

Gait Posture. 2016 Jan;43:125-31. doi: 10.1016/j.gaitpost.2015.08.015. Epub 2015 Sep 25.

Sex differences in neurodevelopmental and neurodegenerative disorders: Focus on microglial function and neuroinflammation during development

Hanamsagar R, Bilbo SD.

J Steroid Biochem Mol Biol. 2016 Jun;160:127-33. doi: 10.1016/j.jsbmb.2015.09.039. Epub 2015 Oct 23.

Comparative analysis of four disease prediction models of Parkinson's disease

Kumudini N, Naushad SM, Alex Stanley B, Niveditha M, Sharmila G, Kumaraswami K, Borghain R, Mridula R, Kutala VK.

Mol Cell Biochem. 2016 Jan;411(1-2):127-34. doi: 10.1007/s11010-015-2574-0. Epub 2015 Oct 5.

Frontotemporal epi- and subdural approach to a cavernous sinus tumor for sphenobasal vein preservation--technical case report

Shibao S, Akiyama T, Tomita H, Kuramae T, Mochizuki Y, Yoshida K.

Neurosurg Rev. 2016 Jan;39(1):169-74; discussion 174. doi: 10.1007/s10143-015-0670-y. Epub 2015 Oct 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias